Dimerix
Dimerix is a clinical-stage biopharmaceutical company leveraging its proprietary Receptor-HIT platform to develop patient-preferred pharmaceutical products for global markets. Their focus is on identifying and developing drugs for areas with unmet needs, particularly in inflammatory diseases affecting the kidney and lungs.
Short position
Dimerix (ASX:DXB) has 0.05% of its shares on issue reported as short positions as of 22 Sept 2026, or about 270,986 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.50% in March 2025. DXB is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4Dimerix (DXB) short interest history
DXB Short Interest History
- 30-day change
- +0.04pp
- 90-day change
- +0.02pp
- 1-year change
- -0.13pp
- All-time high
- 0.50% (March 2025)
- All-time low
- 0.00% (December 2023)
Is DXB heavily shorted?
Not especially: 0.05% short interest is modest by ASX standards, ranking #504 of 799 ASX securities with reported short positions. ASIC requires positions of 0.01% of issued capital or $100,000 (whichever is less) to be reported.
How has DXB's short interest changed recently?
Over the past 30 days Dimerix's short interest has been broadly stable, and over 90 days it has been broadly stable. The current level is 0.05% of shares on issue.
What is the highest DXB's short interest has been?
Since 2020, Dimerix's short interest peaked at 0.50% in March 2025 and bottomed at 0.00% in December 2023.
Where does this data come from?
All figures are sourced from daily ASIC short position reports, published with a four trading-day (T+4) delay. Shorted aggregates the full history since 2020. See our methodology.